Robert Blum exercised 7,500 stock options at $10.60 and sold shares at $76.76, retaining a significant equity stake.
Cytokinetics CEO Robert Blum sold 7,500 shares for $575,700 on August 10, 2026, after exercising stock options at a strike price of $10.60. The shares were sold at a weighted-average price of $76.76, capturing gains from the grant price to current market levels.
The transaction follows Cytokinetics’ market capitalization of $9.6 billion as of the sale date. The company reported trailing twelve-month revenue of $71.0 million and a net loss of $894.0 million. Despite the sale, Blum retains 377,820 direct shares and approximately 172,000 derivative securities.
Blum also holds 4,166 shares indirectly through two irrevocable trusts, maintaining alignment with shareholder interests. The stock closed at $77.49 on the transaction date.